Interestingly, Depatux-m was shown to bind EGFR VIII with higher affinity than cetuximab and to synergistically increase therapeutic efficacy when combined with standard care therapies (e.g., Cisplatin, 5-FU and temozolomide) when treating GBM and HNSCC [117–122, 127]. Here, EGFR is linked to glioblastoma.